OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	82
Your chemo is no good here: management of high-risk MCL	80
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	70
Bispecific antibody therapies	52
Labor and delivery: DIC, HELLP, preeclampsia	50
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	41
Neurological manifestations of MGUS	41
Anticoagulation at the end of life: whether, when, and how to treat	39
On the horizon: upcoming new agents for the management of ITP	38
Mastocytosis demystified	36
Diagnosis and therapeutic decision-making for the neutropenic patient	35
Inpatient recognition and management of HLH	33
Recognizing, defining, and managing CAR-T hematologic toxicities	33
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	32
Has PD-1 blockade changed the standard of care for cHL?	31
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	28
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	27
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	27
Divergent paths: management of early relapsed follicular lymphoma	26
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	26
Selecting initial therapy in CLL	26
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	26
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	25
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	24
How to recognize and manage COVID-19-associated coagulopathy	24

New approaches to tackle cytopenic myelofibrosis	24
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	23
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	23
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	23
Fitness and frailty in myeloma	23
Optimizing outcomes in secondary AML	22
BV and beyond: how to incorporate novel agents into PTCL management	22
MGCS: where do we stand today?	22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	22
How to assess hemostasis in patients with severe liver disease	21
Running interferon interference in treating PV/ET: meeting unmet needs	21
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	21
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	21
Troubleshooting heparin resistance	21
How to manage hemostasis in patients with liver disease during interventions	21
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	20
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	20
Consumptive coagulopathy in the ICU	20
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	20
Management of TKI-resistant chronic phase CML	19
Demystifying autoimmune HIT: what it is, when to test, and how to treat	19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	19
Atypical CML: diagnosis and treatment	19
Hematology 2022—what is complete HLA match in 2022?	19
Hemophilia gene therapy: ushering in a new treatment paradigm?	19
How to diagnose and manage antiphospholipid syndrome	19
How to manage bleeding disorders in aging patients needing surgery	18
What to use to treat AML: the role of emerging therapies	18
Special considerations in GI bleeding in VWD patients	18
Management of limited-stage Hodgkin lymphoma	18
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	18
Managing therapy-associated neurotoxicity in children with ALL	17
Management of marginal zone lymphomas	17
Infectious complications and vaccines	17
Approaches to management of HIT in complex scenarios, including cardiac surgery	17
Thrombosis questions from the inpatient wards	17
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	16
Lower risk but high risk	16
Transplant in AML with measurable residual disease: proceed or defer?	15
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	15
CNS prophylaxis in aggressive B-cell lymphoma	15
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	15
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	15
Organ function indications and potential improvements following curative therapy for sickle cell disease	15
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	15
Alloimmunization and hyperhemolysis in sickle cell disease	15
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	14
What makes a pediatric or young adult patient an appropriate transplant candidate?	14
Thrombocytopenia in pregnancy	14
When does a PNH clone have clinical significance?	14

Treatment of VTE in the thrombocytopenic cancer patient	14
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	14
Pegylated interferon: the who, why, and how	14
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	14
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	14
Cytoreduction for ET and PV: who, what, when, and how?	14
Next-generation therapy for lower-risk MDS	13
What is the ideal approach—doublet, triplet, or quadruplet(s)?	13
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	13
Ph− ALL: immunotherapy in upfront treatment	13
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	13
Clinical manifestations of telomere biology disorders in adults	13
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	13
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	13
Approach to the patient with suspected hypereosinophilic syndrome	12
Novel therapies upon failure of HMA plus venetoclax	12
Should we use bisphosphonates to treat bone complications in sickle cell disease?	12
Frontline treatment in CLL: the case for time-limited treatment	12
The role of stem cell transplant (auto and allo) in PTCL and CTCL	12
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	12
Sequencing bispecific antibodies and CAR T cells for FL	12
Managing side effects: guidance for use of immunotherapies in multiple myeloma	12
Whom should we treat with novel agents? Specific indications for specific and challenging populations	12
What else do I need to worry about when treating graft-versus-host disease?	12